Pharvaris (PHVS) CMO sells 300 shares in scheduled 10b5-1 trade

Rhea-AI Filing Summary

Pharvaris N.V.’s Chief Medical Officer Lu Peng reported a small, scheduled option exercise and share sale. On June 18, 2026, Peng exercised stock options to acquire 300 shares of common stock at $2.59 per share and sold 300 common shares at $34.00 per share in an open-market transaction.

The filing states this was done under a Rule 10b5-1 trading plan. After these transactions, Peng directly holds 65,631 common shares and 205,008 stock options with a $2.59 exercise price expiring on February 3, 2030, indicating the sale involved only a small portion of the overall position.

Insider Trade Summary 10b5-1

Net Seller: 300 shares ($10,200)

Net Sell 3 txns

Insider Lu Peng

Role Chief Medical Officer

Sold 300 shs ($10K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	300	$0.00	--
Exercise	Common Stock	300	$2.59	$777.00
Sale	Common Stock	300	$34.00	$10K

Holdings After Transaction: Stock Option (Right to Buy) — 205,008 shares (Direct, null); Common Stock — 65,931 shares (Direct, null)

Footnotes (1)

1. This is a scheduled exercise and sale from 10b5-1 trading plan. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 300 shares Sale price: $34.00 per share Option exercise size: 300 shares +4 more

7 metrics

Shares sold 300 shares Open-market sale of common stock at $34.00 on June 18, 2026

Sale price $34.00 per share Price for 300 Pharvaris common shares sold

Option exercise size 300 shares Common shares acquired via option exercise

Option exercise price $2.59 per share Strike price for exercised Pharvaris stock options

Shares held after 65,631 shares Direct Pharvaris common stock ownership following transactions

Options remaining 205,008 options Stock options outstanding after exercise, strike $2.59, expiring Feb 3, 2030

Underlying shares for options 245,308 shares Underlying Pharvaris common stock referenced for the option award

Key Terms

Rule 10b5-1 trading plan, open-market sale, Stock Option (Right to Buy), Chief Medical Officer, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This is a scheduled exercise and sale from 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

""security_title": "Stock Option (Right to Buy)""

Chief Medical Officer financial

""officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Exercise or conversion of derivative security financial

""transaction_code_description": "Exercise or conversion of derivative security""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Peng

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		M(1)		300	A	$2.59	65,931	D
Common Stock	06/18/2026		S(1)		300	D	$34	65,631	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	06/18/2026		M(1)			300	(2)	02/03/2030	Common Stock	245,308	$0.00	205,008	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Peng Lu	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Pharvaris (PHVS) report for Lu Peng?

Lu Peng, Chief Medical Officer of Pharvaris, exercised options for 300 common shares at $2.59 and sold 300 shares at $34.00. The transactions were reported as an open-market sale paired with an option exercise on June 18, 2026, under a Rule 10b5-1 plan.

How many Pharvaris (PHVS) shares does Lu Peng hold after the Form 4?

After the reported transactions, Lu Peng directly holds 65,631 Pharvaris common shares. In addition, the filing shows 205,008 stock options outstanding with a $2.59 exercise price expiring on February 3, 2030, providing significant remaining exposure to Pharvaris equity beyond the small sale.

Was Lu Peng’s Pharvaris (PHVS) share sale part of a 10b5-1 trading plan?

Yes. A footnote states the option exercise and sale were a scheduled transaction under a Rule 10b5-1 trading plan. Such plans pre-arrange trades, meaning the timing is set in advance and is typically viewed as routine portfolio management rather than a discretionary market-timing decision.

What were the prices in Lu Peng’s Pharvaris (PHVS) Form 4 transactions?

The Form 4 reports an option exercise price of $2.59 per share and an open-market sale price of $34.00 per share for Pharvaris common stock. These figures show the spread between the option strike price and the sale price realized in the scheduled transaction.

What stock options does Lu Peng retain in Pharvaris (PHVS)?

The filing shows Lu Peng retains 205,008 stock options, each with a $2.59 exercise price and an expiration date of February 3, 2030. These options relate to Pharvaris common stock and represent a substantial ongoing incentive and exposure to the company’s future performance.